University Of Minnesota
- Address
- 2221 University Avenue Southeast Suite 200
Sponsor Overview
Specializations
COVID-19 Therapeutics
Clinical research activity centers on COVID-19 treatment in both hospitalized adults and outpatient populations, with attention to improving clinical status and recovery during active infection.
- Antiviral therapy
- Anti-coronavirus immunoglobulin
- Standard of care combination treatment
Studies include interventions intended to address acute SARS-CoV-2 infection across different care settings.
Respiratory Infection Research
The sponsor supports trials focused on acute respiratory infections, with particular emphasis on treatment strategies for patients requiring hospital care.
- Hospital-based respiratory infection management
- Therapeutic strategy evaluation
- Clinical recovery outcomes
This work is directed toward identifying interventions for severe viral respiratory illness in adult populations.
Immune Modulation
Research interests include immune-modulating approaches for COVID-19, especially strategies designed to influence disease course in hospitalized patients.
- Immune modulation
- Adjunctive treatment strategies
- Recovery through Day 60
These studies examine immune-based interventions alongside established supportive care.
Multicenter Clinical Trials
The sponsor is involved in multicenter research spanning multiple collaborating sites and countries, supporting coordinated evaluation of therapies for infectious disease.
- Randomized controlled trials
- Adaptive trial platforms
- International collaboration
Trial activity reflects a broad network for testing interventions in diverse patient populations affected by viral respiratory illness.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Shionogi Protease Inhibitor (S-217622) |  Denmark Germany Greece Ireland Poland Spain | Not Recruiting |
| Evaluation of Abatacept and Placebo in Hospitalized Adults with COVID-19: A Randomized, Controlled Trial on Immune Modulation Strategies |  Cyprus Denmark France Germany Greece Ireland Poland Spain Sweden | Not Recruiting |
| Evaluation of Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin Efficacy and Safety in Early-Stage COVID-19 Adult Outpatients: A Randomized, Double-Blind, Placebo-Controlled Trial | Denmark Greece Spain | Not Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 45 sites across their trial portfolio.
Therapeutic Focus
- 1.Virus Diseases3 trials182 other sponsors
- 2.Respiratory Tract Diseases2 trials277 other sponsors
Partnered Research Centres
45 centres- Address
- Moelleparkvej 4, 9000 Aalborg
- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Vassilissis Sofias Avenue 80, 115 28 Athens
- Address
- 46 Rue Henri Huchard, 75877 Paris
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Nielsine Nielsens Vej 6A, 2400 Copenhagen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to University Of Minnesota.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.